BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18072423)

  • 1. [Rituximab (antiCD20 monoclonal antibody) and molecular-biological negativity in the treatment of patients with follicular lymphoma--a way to a cure?--Editorial].
    Trnený M
    Vnitr Lek; 2007 Oct; 53(10):1029-30. PubMed ID: 18072423
    [No Abstract]   [Full Text] [Related]  

  • 2. [Achieving Bcl-2/IgH negativity in peripheral blood/bone marrow after therapy implies better prognosis for patients with follicular lymphoma].
    Belada D; Smolej L; Stepánková P; Beránek M; Dvoráková D; Bukac J; Malý J
    Vnitr Lek; 2007 Oct; 53(10):1057-63. PubMed ID: 18072430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.
    Borradori L; Lombardi T; Samson J; Girardet C; Saurat JH; Hügli A
    Arch Dermatol; 2001 Mar; 137(3):269-72. PubMed ID: 11255323
    [No Abstract]   [Full Text] [Related]  

  • 5. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
    Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.
    Buchegger F; Press OW; Delaloye AB; Ketterer N
    Oncologist; 2008 Jun; 13(6):657-67. PubMed ID: 18586921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathogenesis and treatment of follicular lymphoma].
    Nishikori M
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():477-81. PubMed ID: 23134002
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.
    Takao T; Kobayashi Y; Kuroda J; Omoto A; Nishimura T; Kamitsuji Y; Fukiya E; Nakamura C; Kimura S; Yoshikawa T
    Am J Hematol; 2004 Dec; 77(4):419-20. PubMed ID: 15551361
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
    Colombat P; Salles G; Brousse N; Eftekhari P; Soubeyran P; Delwail V; Deconinck E; Haïoun C; Foussard C; Sebban C; Stamatoullas A; Milpied N; Boué F; Taillan B; Lederlin P; Najman A; Thièblemont C; Montestruc F; Mathieu-Boué A; Benzohra A; Solal-Céligny P
    Blood; 2001 Jan; 97(1):101-6. PubMed ID: 11133748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular lymphoma, survival, and rituximab: is it time to declare victory?
    Horning SJ
    J Clin Oncol; 2008 Oct; 26(28):4537-8. PubMed ID: 18662966
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Landgren O; Dunleavy K; Wilson WH
    J Natl Cancer Inst; 2009 Sep; 101(18):1287-8; author reply 1289-90. PubMed ID: 19687413
    [No Abstract]   [Full Text] [Related]  

  • 14. Remission of transient acantholytic dermatosis after the treatment with rituximab for follicular lymphoma.
    Ishibashi M; Nagasaka T; Chen KR
    Clin Exp Dermatol; 2008 Mar; 33(2):206-7. PubMed ID: 18076680
    [No Abstract]   [Full Text] [Related]  

  • 15. [New data prove therapeutic superiority. MabThera in follicular and mantle cell lymphoma].
    Krankenpfl J; 2002; 40(5-6):161. PubMed ID: 12271501
    [No Abstract]   [Full Text] [Related]  

  • 16. Cryptic insertion of BCL2 gene into immunoglobulin heavy locus in follicular lymphoma with t(6;9)(p23;p13).
    Yamamoto K; Okamura A; Inui Y; Yakushijin K; Murayama T; Matsuoka H; Minami H
    Leuk Res; 2012 Sep; 36(9):e202-5. PubMed ID: 22658849
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified.
    Hirata Y; Yokote T; Kobayashi K; Nakayama S; Miyoshi T; Akioka T; Hara S; Tsuji M; Takubo T; Hanafusa T
    Leuk Res; 2009 Jun; 33(6):e13-6. PubMed ID: 18995899
    [No Abstract]   [Full Text] [Related]  

  • 18. [Update on lymphomas: 1997, a profitable year].
    Coiffier B; Salles G
    Bull Cancer; 1998 Jan; 85(1):45-7. PubMed ID: 9752346
    [No Abstract]   [Full Text] [Related]  

  • 19. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
    Foran JM; Gupta RK; Cunningham D; Popescu RA; Goldstone AH; Sweetenham JW; Pettengell R; Johnson PW; Bessell E; Hancock B; Summers K; Hughes J; Rohatiner AZ; Lister TA
    Br J Haematol; 2000 Apr; 109(1):81-8. PubMed ID: 10848785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predictive for response of follicular and mantle-cell lymphoma to rituximab.
    Pfreundschuh M
    Nat Clin Pract Oncol; 2006 Apr; 3(4):184-5. PubMed ID: 16596141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.